An observational study in Schizophrenia, sponsored by AstraZeneca. Completed at 25 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-24.
Sponsored by AstraZeneca · Observational
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
3,470 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.
This study's enrollment of 339 is above the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Stabilized outpatients with a diagnosis of schizophrenia
Exclusion Criteria:
Morisky Green Questionnaire
Time frame: baseline, at months 3 and 6
Clinical Global Impression- Schizophrenia (CGI-SCH)
Time frame: baseline, at months 3 and 6
Register of Adherence to Treatment (RAT)
Time frame: baseline, at months 3 and 6
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca